Biocompatibility of Chitosan Carriers with Application in Drug Delivery
Source abstract
Abstract
Chitosan is one of the most used polysaccharides in the design of drug delivery strategies for administration of either biomacromolecules or low molecular weight drugs. For these purposes, it is frequently used as matrix forming material in both nano and micron-sized particles. In addition to its interesting physicochemical and biopharmaceutical properties, which include high mucoadhesion and a great capacity to produce drug delivery systems, ensuring the biocompatibility of the drug delivery vehicles is a highly relevant issue. Nevertheless, this subject is not addressed as frequently as desired and even though the application of chitosan carriers has been widely explored, the demonstration of systems biocompatibility is still in its infancy. In this review, addressing the biocompatibility of chitosan carriers with application in drug delivery is discussed and the methods used in vitro and in vivo, exploring the effect of different variables, are described. We further provide a discussion on the pros and cons of used methodologies, as well as on the difficulties arising from the absence of standardization of procedures.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Polymer Surface Interaction Studies · Hydrogels: synthesis, properties, applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Centre for Molecular and Structural Biomedicine (CBME), Institute for Biotechnology and Bioengineering (IBB), Faculty of Sciences and Technology, University of Algarve, Campus de Gambelas, Faro 8005-139, Portugal
Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, Campus Vida, Santiago de Compostela 15782, Spain
References (100+)
Show source-provided references
1. Therapeutic application of peptides and proteins: Parenteral forever?10.1016/j.tibtech.2009.07.009 ↗
2. Nano- and micro-particulate carriers for pulmonary drug delivery
3. Molecular aspects of mucoadhesive carrier development for drug delivery and improved absorption10.1163/156856208X393464 ↗
4. Chitosan-based delivery systems for protein therapeutics and antigens10.1016/j.addr.2009.11.009 ↗
5. The potential of chitosan for pulmonary drug delivery10.1016/S1773-2247(10)50004-2 ↗
6. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers10.1016/0378-5173(92)90353-4 ↗
7. Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems10.1042/bj3480557 ↗
8. Advances and potential applications of chitosan derivatives as mucoadhesive biomaterials in modern drug delivery10.1211/jpp.58.8.0002 ↗
9. Chitosan chemistry and pharmaceutical perspectives10.1021/cr030441b ↗
10. The safety of chitosan as a pharmaceutical excipient10.1016/j.yrtph.2009.09.015 ↗
11. Felton, G. (2011). Biodegradable Polymers: Processing, Degradation and Applications, Nova Science Publisher.
12. Chitosan—A versatile semi-synthetic polymer in biomedical applications10.1016/j.progpolymsci.2011.02.001 ↗
13. Main properties and current applications of some polysaccharides as biomaterials10.1002/pi.2378 ↗
14. Chitosan/carrageenan nanoparticles: Effect of cross-linking with tripolyphosphate and charge ratios10.1016/j.carbpol.2012.03.010 ↗
15. Chitin and chitosan: Functional biopolymers from marine crustaceans10.1007/s10126-005-0097-5 ↗
16. Biodegradation, biodistribution and toxicity of chitosan10.1016/j.addr.2009.09.004 ↗
17. Biomedical applications of chitin, chitosan and their derivatives10.1081/MC-100100579 ↗
18. Preparation and solubility in acid and water of partially deacetylated chitins10.1021/bm000036j ↗
19. The potential of chitosan for the oral administration of peptides10.1517/17425247.2.5.843 ↗
20. Potential applications of chitosan in oral mucosal delivery10.1016/S1773-2247(10)50003-0 ↗
21. Recent advances of chitosan nanoparticles as drug carriers
22. Chitosan formulations as carriers for therapeutic proteins10.2174/157016311796799035 ↗
23. Targeted delivery of low molecular drugs using chitosan and its derivatives10.1016/j.addr.2009.10.003 ↗
24. Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications10.2217/17435889.3.3.367 ↗
25. The performance of nanocarriers for transmucosal drug delivery10.1517/17425247.3.4.463 ↗
26. Chitosan-coated solid lipid nanoparticles for insulin delivery10.1016/B978-0-12-391860-4.00015-X ↗
27. Chitosan nanoparticles: a survey of preparation methods10.3109/1061186X.2011.654121 ↗
28. Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles
29. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administration10.1016/j.colsurfb.2012.01.001 ↗
30. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration10.1016/j.ejps.2012.01.002 ↗
31. Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge10.1371/journal.pone.0027605 ↗
32. Evaluation of mucoadhesive PLGA microparticles for nasal immunization10.1208/s12248-009-9169-1 ↗
33. Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome10.1016/j.ijpharm.2012.04.007 ↗
34. Effectiveness of submicronized chitosan-coated liposomes in oral absorption of indomethacin10.3109/08982104.2011.621128 ↗
35. Enhancement of nasal absorption of insulin using chitosan nanoparticles10.1023/A:1018908705446 ↗
36. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice10.1016/j.ejpb.2003.09.006 ↗
37. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2)10.1023/A:1018967116988 ↗
38. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro10.1016/0168-3659(95)00146-8 ↗
39. Transmucosal macromolecular drug delivery10.1016/j.jconrel.2004.07.030 ↗
40. Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A10.1016/S0378-5173(01)00760-8 ↗
41. The potential of chitosan in enhancing peptide and protein absorption across the TR146 cell culture model—An in vitro model of the buccal epithelium10.1023/A:1014220832384 ↗
42. Microencapsulated chitosan nanoparticles for pulmonary protein delivery: In vivo evaluation of insulin-loaded formulations10.1016/j.jconrel.2011.08.008 ↗
43. Chitosan-based systems for the delivery of vaccine antigens10.1586/erv.09.47 ↗
44. Chitosan derivatives with antimicrobial, antitumour and antioxidant activities—A review10.2174/138161211798194468 ↗
45. Chitosan modification and pharmaceutical/biomedical applications10.3390/md8071962 ↗
46. The enzymatic degradation and swelling properties of chitosan matrices with different degrees of N-acetylation10.1016/j.carres.2005.07.022 ↗
47. Effects of nanomaterial physicochemical properties on in vivo toxicity10.1016/j.addr.2009.03.010 ↗
48. N-acetylation in chitosan and the rate of its enzymic hydrolysis10.1016/0142-9612(89)90066-5 ↗
49. Studies on chitosan: 4. Lysozymic hydrolysis of partially N-acetylated chitosans10.1016/S0141-8130(05)80032-7 ↗
50. Lysozyme degradation of partially deacetylated chitin, its films and hydrogels10.1016/0142-9612(82)90043-6 ↗
51. Relationship between physicochemical characteristics and functional properties of chitosan10.1016/j.eurpolymj.2005.04.041 ↗
52. Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells10.1023/A:1016444808000 ↗
53. Polymeric carriers: Preclinical safety and the regulatory implications for design and development of polymer therapeutics10.1016/j.addr.2009.06.003 ↗
54. Williams, D. (1987). Definitions in Biomaterials, Elsevier.10.1016/B978-0-408-03070-0.50007-8 ↗
55. On the mechanisms of biocompatibility10.1016/j.biomaterials.2008.04.023 ↗
56. Examination of cell–host–biomaterial interactions via high-throughput technologies: A re-appraisal10.1016/j.biomaterials.2010.05.029 ↗
57. Biocompatibility and drug delivery systems10.1039/C0SC00203H ↗
58. Guyton, A., and Hall, J. (2011). Textbook of Medical Physiology, Elsevier. [12th].
59. Endocytosis of nanomedicines10.1016/j.jconrel.2010.01.036 ↗
60. Uptake and cytotoxicity of chitosan molecules and nanoparticles: Effects of molecular weight and degree of deacetylation10.1023/B:PHAM.0000016249.52831.a5 ↗
61. (2009). Biological Evaluation of Medical Devices Part 5: Tests for in vitro Cytotoxicity, 10993-5: 2009.
62. (2009). Biological Evaluation of Medical Devices Part 1: Evaluation and Testing, 10993-1: 2009.
63. (2003). Biological Evaluation of Medical Devices Part 3: Tests for Genotoxicity, Carcinogenicity, and Reproductive Toxicity, 10993-3: 2003.
64. Cytotoxicity of nanoparticles10.1002/smll.200700595 ↗
65. In vitro models in biocompatibility assessment for biomedical-grade chitosan derivatives in wound management10.3390/ijms10031300 ↗
66. (2006). Biological Evaluation of Medical Devices Part 2: Animal Welfare Requirements, 10993-2: 2006.
67. The MTT assay as tool to evaluate and compare excipient toxicity in vitro on respiratory epithelial cells10.1016/j.ijpharm.2011.03.053 ↗
68. Comparative study of the time dependency of cell death assays
69. Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations10.1021/bp00024a017 ↗
70. Assessing cytotoxicity of (iron oxide-based) nanoparticles: An overview of different methods exemplified with cationic magnetoliposomes10.1002/cmmi.282 ↗
71. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line10.1016/j.taap.2008.09.030 ↗
72. Cell viability assays: Introduction10.1007/978-1-61779-108-6_1 ↗
73. Detection of dead cells and measurement of cell killing by flow cytometry10.1016/S0022-1759(00)00232-5 ↗
74. Low-potency glucocorticoid hydrocortisone has similar neurotoxic effects as high-potency glucocorticoid dexamethasone on neurons in the immature chicken cerebellum10.1016/j.brainres.2008.07.095 ↗
75. Validation of an LDH assay for assessing nanoparticle toxicity10.1016/j.tox.2011.06.011 ↗
76. In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride10.1016/j.toxlet.2005.07.001 ↗
77. Use of lactate dehydrogenase release to assess changes in culture viability10.1007/BF00365494 ↗
78. Assessments of lysosomal membrane responses to stresses with neutral red retention assay and its potential application in the improvement of bivalve aquaculture10.5897/AJB10.2283 ↗
79. Comparison of alamar blue and MTT assays for high through-put screening10.1016/j.tiv.2004.03.012 ↗
80. Evaluation of hepatic subcellular fractions for Alamar blue and MTT reductase activity10.1016/S0887-2333(01)00014-5 ↗
81. Mitochondrial and nonmitochondrial reduction of MTT: Interaction of MTT with TMRE, JC-1, and NAO mitochondrial fluorescent probes10.1002/cyto.10080 ↗
82. Toxicity and antibacterial assessment of chitosancoated silver nanoparticles on human pathogens and macrophage cells
83. Design and characterization of antitumor drug paclitaxel-loaded chitosan nanoparticles by W/O emulsions10.1016/j.ijbiomac.2011.12.034 ↗
84. Development of new chitosan/carrageenan nanoparticles for drug delivery applications10.1002/jbm.a.32466 ↗
85. Doxorubicin-incorporated nanoparticles composed of poly(ethylene glycol)-grafted carboxymethyl chitosan and antitumor activity against glioma cells in vitro10.1016/j.colsurfb.2010.03.037 ↗
86. 5-flourouracil loaded N,O-carboxymethyl chitosan nanoparticles as an anticancer nanomedicine for breast cancer10.1166/jbn.2012.1365 ↗
87. Effect of chitosan-coated alginate microspheres on the permeability of Caco-2 cell monolayers10.1080/03639040600735020 ↗
88. Strong electronic charge as an important factor for anticancer activity of chitooligosaccharides (COS)10.1016/j.lfs.2005.09.039 ↗
89. In vitro permeability enhancement in intestinal epithelial cells (Caco-2) monolayer of water soluble quaternary ammonium chitosan derivatives10.1208/s12249-010-9399-7 ↗
90. Uptake and cytotoxicity of chitosan nanoparticles in human liver cells10.1016/j.taap.2010.08.029 ↗
91. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro10.1016/j.ejps.2007.02.008 ↗
92. Highly efficient system to deliver taxanes into tumor cells: Docetaxel-loaded chitosan oligomer colloidal carriers10.1021/bm800298u ↗
93. Enhanced antibacterial effect of ceftriaxone sodium-loaded chitosan nanoparticles against intracellular Salmonella typhimurium10.1208/s12249-012-9758-7 ↗
94. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain10.1016/j.biomaterials.2009.09.104 ↗
95. In vitro cytotoxicity testing of chitosan-containing polyelectrolyte complexes10.1023/A:1008890829959 ↗
96. Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells
97. One-step fabrication of biocompatible chitosan-coated ZnS and ZnS:Mn2+ quantum dots via a γ-radiation route10.1186/1556-276X-6-591 ↗
98. Surface modification of gold and quantum dot nanoparticles with chitosan for bioapplications10.1002/jbm.a.30410 ↗
99. Facilitated nanoscale delivery of insulin across intestinal membrane models10.1016/j.ijpharm.2011.04.003 ↗
100. Polyelectrolyte nanoparticles based on water-soluble chitosan–poly(l-aspartic acid)–polyethylene glycol for controlled protein release10.1016/j.carres.2009.04.018 ↗